Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

BACKGROUND: T cell-based immunotherapies using chimeric antigen receptors (CAR) or bispecific antibodies (BsAb) have produced impressive responses in hematological malignancies. However, major hurdles remained, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, reliance...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong A, Santich, Brian H, Xu, Hong, Lum, Lawrence G, Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126293/
https://www.ncbi.nlm.nih.gov/pubmed/33986124
http://dx.doi.org/10.1136/jitc-2020-002222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126293/
https://www.ncbi.nlm.nih.gov/pubmed/33986124
http://dx.doi.org/10.1136/jitc-2020-002222

Ejemplares similares